<DOC>
	<DOCNO>NCT02428543</DOCNO>
	<brief_summary>This project part joint ALFA GOELAM strategy aim improve survival patient newly diagnose Acute Myeloid Leukemia ( AML ) age 18-70 year . The basis strategy evaluate intensified conventional chemotherapy target drug select disease-risk subgroup adult patient non promyelocytic AML . Participation propose almost adult patient France age 18-70 year diagnose AML . FLT3 genetic alteration include FLT3 somatic point mutation within second tyrosine kinase domain internal duplication juxta-membrane domain . This alteration refer FLT3-ITD . The FLT3-ITD mutation find around 30 % patient cytogenetically normal AML . Patients FLT3-ITD genotype report poor outcome treat conventional chemotherapy estimate 4-year relapse-free survival 25 % ( Schlenk et al . N Engl J Med 2008 ) . More recently , prognostic relevance FLT3-ITD study context integrate genetic profiling . This confirm genetic complexity AML also FLT3-ITD associate reduced overall survival intermediate-risk AML . A multivariate analysis several genetic alteration reveal FLT3-ITD primary predictor patient outcome . FLT3-ITD mutation classify 3 category : 1 ) FLT3-ITD +8 , TET2 , DNMT3A MLL-PTD mutation ( 3-year OS 14.5 % ) ; 2 ) FLT3-ITD wild type CEBPA , TET2 , DNMT3 MLL-PTD ( 3-year OS 35.2 % ) 3 ) FLT3-ITD CEBPA mutation ( 3-year OS 42 % ) ( Patel JP et al . N Engl J Med 2012 ) . However , FLT3-ITD predictor response induction therapy , allow introduction target therapy induction course . Several FLT3 inhibitor evaluate currently test set relapse AML . In trial date , patient eligible FLT3-ITD mutation present . Disappointing result report first generation FLT3 inhibitor , include lestaurtinib ( CEP-701 ) , midostaurin ( PKC-412 ) sorafenib . Second generation FLT3 inhibitor quizartinib ( AC220 ) currently investigation promise result . However , hematologic toxicity AC220 likely present major limitation evaluate AC220 combined standard high-dose chemotherapy . Ponatinib ( AP24534 ) third generation tyrosine kinase inhibitor target BCR-ABL tyrosine kinase domain . Ponatinib rationally design extensive network optimize molecular contact triple bond accommodate T315I mutation , major cause resistance tyrosine kinase inhibitor chronic advanced phase chronic myelogenous leukemia ( CML ) . Ponatinib also inhibit SRC ( IC50 : 5.4 nM ) member VEGFR , FGFR , PDGFR family receptor tyrosine kinase ( O'Hare T , Cancer Cell 2009 ) . Despite low activity FLT3 base IC50 value ( FLT3 IC50 : 12.6 nM compare BCR IC50 : 0.37 nM ) , ponatinib recently report significant cellular activity MV4-11 cell line harbor FLT3-ITD activate mutation . Ponatinib-induced apoptosis maximal 10 nM vitro single dose 5 10 mg/kg strong inhibitory effect vivo mouse bear MV4-11 xenograft . Primary blast cell 4 FLT3-ITD AML patient also test ponatinib reduce viability ( IC50 : 4 nM ) whereas activity show FLT3-ITD-negative blast cell ( Gozgit JM et al . Mol Cancer Ther 2011 ) . Preliminary data phase I clinical trial show 15 mg ponatinib associate Cmax 51.1 nM . Cmax increase 111 nM 149 nM 30 mg 45 mg cohort respectively . The trough concentration 55.3 nM 61.9 nM 30 mg 45 mg dos respectively ( Ariad clinical investigator 's brochure , version 3 ) . Results ongoing phase II trial CML patient suggest hematological toxicity profile ponatinib comparable nilotinib dasatinib , successfully combine conventional chemotherapy . Investigators thus aim combine ponatinib cytarabine FLT3-ITD AML patient first complete remission .</brief_summary>
	<brief_title>Ponatinib FLT3-ITD Acute Myelogenous Leukemia</brief_title>
	<detailed_description />
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Ponatinib</mesh_term>
	<criteria>1. Patients age 18 5560 year : Cohort A b Patients age 5560 70 year : Cohort B 2 . Signed informed consent 3 . Acute myeloid leukemia first complete remission 4 . Platelets ≥ 100 Giga/l ; Neutrophils ≥ 1 Giga/l 5 . Intermediate risk karyotype FLT3ITD activate mutant detect diagnosis ( mutant FLT3/wildtype allelic ratio high 10 % ) 6 . Induction intensive chemotherapy , dose dense sequential induction 3 + 7 like regimen ( daunorubicin idarubicin ) Cohort A inclusion ALFA backbone cohort B ( 3 + 7 like regimen approval study coordinator ) 7 . Pancreatic function within normal range 8 . AST ALT less equal 2.5 fold upper normal range , bilirubin le equal 1.5 fold upper normal range 9 . Serum creatinine less equal 1.5 fold upper normal range 10 . Two planned consolidation course highdose cytarabine ( HDAC , Cohort A ) intermediate dose cytarabine ( IDAC , Cohort B ) 1 . Acute promyelocytic leukemia 2 . Inclusion ALFA 0702 trial 3 . Patient eligible bone marrow transplant identify donor 4 . Transformation myeloproliferative myelodysplastic syndrome 5 . Known central nervous system involvement . 6 . Uncontrolled bacterial , viral fungal infection 7 . Other active malignancy 8 . Previous episode pancreatitis 9 . Hypertriglyceridemia &gt; 4.5 g/L 10 . Lipase &gt; 1.5 × ULN , amylase &gt; 1.5 x ULN relate leukemia 11 . QTc &gt; 470 m ( Bazett formula ) 12 . Significant uncontrolled active cardiovascular disease , specifically include , restrict : Myocardial infarction , unstable angina and/or congestive heart failure within 3 month prior randomization History clinically significant ( determined treat physician ) atrial arrhythmia ventricular arrhythmia Uncontrolled hypertension Taking medication know associated Torsades de Pointes</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>FLT3-ITD patient first complete remission</keyword>
</DOC>